ACM
CLYM

ADAR1 Capital Management’s Climb Bio CLYM Stock Holding History

ADAR1 Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.09M Sell
597,662
-834,813
-58% -$4.82M 0.25% 88
2025
Q4 		$5.73M Buy
1,432,475
+1,298,945
+973% +$3.12M 0.43% 53
2025
Q3 		$268K Buy
133,530
+14,210
+12% +$26.4K 0.03% 168
2025
Q2 		$148K Hold
119,320
– – 0.02% 163
2025
Q1 		$146K Buy
119,320
+71,195
+148% +$115K 0.03% 155
2024
Q4 		$86.6K Sell
48,125
-115,318
-71% -$417K 0.02% 183
2024
Q3 		$832K Buy
163,443
+65,748
+67% +$465K 0.14% 88
2024
Q2 		$695K Buy
+97,695
New +$650K 0.14% 83

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return